Core Insights - PAVmed Inc. completed a private placement equity financing for its subsidiary Veris Health, raising $2.5 million at a pre-money valuation of approximately $35 million [1][2][3] Group 1: Financing Details - Veris Health sold shares at $1.40 per share, with proceeds aimed at advancing its implantable physiological monitor through FDA clearance expected in 2026 [2][3] - The financing follows a previous $2.4 million round completed earlier in the year, indicating ongoing investor interest and confidence in Veris Health's potential [1][2] Group 2: Product and Technology - Veris Health focuses on personalized cancer care through remote patient monitoring using implantable biologic sensors and connected external devices [2][4] - The Veris Cancer Care Platform integrates remote physiological data collection, symptom reporting, telehealth capabilities, and electronic health record integration to enhance patient care [4][5] Group 3: Strategic Importance - The financing is seen as a significant milestone for both PAVmed and Veris, providing necessary capital to fund the development and commercialization of the implantable physiological monitor [3][4] - The monitor is expected to serve as a key differentiator in the market, enhancing personalized care in conjunction with the Veris Cancer Care Platform [3][5]

Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery networkNEW YORK, June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, int ...

Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – JamesNEW YORK, June 3, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has entered into a strategic ...

Core Points - Lucid Diagnostics Inc. will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index effective after the close of U.S. equity markets on June 27, 2025, as part of the 2025 annual reconstitution [1][2] - This inclusion is expected to enhance Lucid's visibility and access to a broader range of institutional investors, reflecting the company's progress in enhancing shareholder value over the past year [2] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [4] - The company's EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device are the first and only commercially available tools aimed at preventing cancer through early detection of esophageal precancer in at-risk patients [4] Market Context - The Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index is a subset focused on small-cap companies [2] - Approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes, indicating the significance of these indices for institutional investors and investment managers [2]

Core Viewpoint - Lucid Diagnostics Inc. has secured capital to extend its operational runway significantly, positioning the company to capitalize on upcoming reimbursement milestones and accelerate commercialization efforts for its EsoGuard product [4][6]. Business Highlights - The company is expanding cash-pay and contracted programs targeting concierge medicine practices and self-insured employers, while also gaining traction with regional commercial insurers for EsoGuard coverage [4]. - A partnership with a major health system has been established to launch a comprehensive EsoGuard esophageal precancer testing program, enhancing access for at-risk patients [6]. - The company has launched the "Embrace the Future" campaign to promote its EsoCheck® Cell Collection Device, which features innovative technology compared to traditional methods [6]. - A National Cancer Institute-sponsored study has shown that EsoGuard effectively detects esophageal precancer in at-risk patients without GERD, potentially increasing market opportunity by up to 70% [6]. Financial Results - For the three months ended March 31, 2025, Lucid processed 3,034 EsoGuard tests and recognized $0.8 million in revenue from EsoGuard [6]. - The company reported operating expenses of approximately $13.3 million, including $1.0 million in stock-based compensation, leading to a GAAP net loss of approximately $36.0 million or $(0.52) per share [6][9]. - The non-GAAP adjusted loss for the same period was approximately $11.2 million or $(0.16) per share [7][11]. - As of March 31, 2025, Lucid had cash and cash equivalents of $25.2 million, an increase from $22.4 million as of December 31, 2024, and completed a public offering for net proceeds of $16.1 million [10].

Conference Call and Webcast at 8:30 AM Eastern TimeNEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a busine ...

Conference Call and Webcast at 8:30 AM Eastern TimeNEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, inclu ...